Hepatologic Research

< Inflammatory and Cardiovascular Disorders

Research group

Group Leader

Ricard Solà Lamoglia

Since 2000, our work group has followed various lines of clinical research: The natural history of decompensated cirrhosis, ascites, renal insufficiency and infections; The virological response and viral kinetics during hepatitis C treatment in patients with or without HIV coinfection; The adherence to hepatitis C treatment and the study, prevention and treatment of the psychiatric pathology associated with the interferon and the progression of fibrosis in Hepatitis C with or without HIV coinfection. Recently we also have initiated diferent studies in Hepatitis B (particularly adherence to the treatment and reactivation, treatment and predictors of curation), hepatocellular carcinoma (natural history and impact of different etiologies) and non-alcoholic steatohepatitis (NASH).

2017

Members

José Antonio Carrión Rodríguez (Researcher)

Montserrat García Retortillo (Researcher)

María Teresa Broquetas González (PhD Student)

Núria Cañete Hidalgo (PhD Student)

Susana Coll Estrada (PhD Student)

Marc Puigvehí Badosa (PhD Student)

Maria Dolors Giménez Romaní (Technician)

Ana Viu Soto (Technician)

Diego Lázaro Agudo (Research Assistant)

Main Publications

• Fernández-Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernández I, Baliellas C, Carrión JA, de la Mata M, Buti M, Castells L, Albillos A, Romero M, Turnes J, Pons C, Moreno-Planas JM, Moreno-Palomares JJ, Fernández-Rodríguez C, García-Samaniego J, Prieto M, Fernández-Bermejo M, Salmerón J, Badia E, Salcedo M, Herrero JI, Granados R, Blé M, Mariño Z, Calleja JL. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry. Hepatology 2017; 65(6): 1810-1822. IF 13.246. D1.

• Lens S, Fernández I, Rodríguez-Tajes S, Hontangas V, Vergara M, Forné M, Calleja JL, Diago M, Llaneras J, Llerena S, Torras X, Sacristán B, Roget M, Fernández-Rodríguez CM, Navascués MC, Fuentes J, Sánchez-Ruano JJ, Simón MÁ, Sáez-Royuela F, Baliellas C, Morillas R, Forns X, Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group (...Carrión JA...). Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. Am J Gastroenterol 2017; 112(9): 1400-1409. IF 9.566. D1.

• Londoño MC, Carrión JA, Forns X. Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy-authors' reply. Aliment Pharm Therap 2017; 45(12): 1559-1560. IF 7.286. D1.

• Londoño MC, Lens S, Mariño Z, Bonacci M, Ariza X, Broquetas T, Pla A, Bartres C, Adriani MV, Rodríguez-Tajes S, Costa J, Carrión JA, Pérez-Del-Pulgar S, Forns X. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. Aliment Pharm Therap 2017; 45(8): 1156-1161. IF 7.286. D1.

• Navarro J, Laguno M, Vílchez HH, Guardiola JM, Carrión JA, Force L, Cairó M, Cifuentes C, Vilaró J, Cucurull J, Marco A, Roget M, Erice E, Crespo M, Catalano-Balear Study Group (...Puigvehí M...). Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. J Antimicrob Chemother 2017; 72(10): 2850-2856. IF 5.071. D1.

• Alonso S, Riveiro-Barciela M, Fernández I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernández-Carrillo C, Polo B, Carrión JA, Gómez A, Devesa MJ, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio JM, Rubín A, Salmerón J, Badia E, Planas JM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez CM. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepatitis 2017; 24(4): 304-311. IF 4.122. Q1.

• Perelló C, Carrión JA, Ruiz-Antorán B, Crespo J, Turnes J, Llaneras J, Lens S, Delgado M, García-Samaniego J, García-Paredes F, Fernández I, Morillas RM, Rincón D, Porres JC, Prieto M, Lázaro M, Fernández-Rodríguez C, Hermo JA, Rodríguez M, Herrero JI, Ruiz P, Fernández JR, Macías M, Pascasio JM, Moreno JM, Serra MÁ, Arenas J, Real Y, Jorquera F, Calleja JL, Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. J Viral Hepatitis 2017; 24(3): 226-237. IF 4.122. Q1.

• Mariño Z, Pascasio-Acevedo JM, Gallego A, Diago M, Baliellas C, Morillas R, Prieto M, Moreno JM, Sánchez-Antolín G, Vergara M, Forné M, Fernández I, Castro MA, Pascual S, Gómez A, Castells L, Montero JL, Crespo J, Calleja JL, García-Samaniego J, Carrión JA, Arencibia AC, Blasco A, López-Núñez C, Sánchez-Ruano J, Gea F, Giráldez A, Cabezas J, Hontangas V, Torras X, Castellote J, Romero-Gómez M, Turnes J, de Artaza T, Narváez I, Cuervas-Mons I, Forns X. High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. Liver Int 2017; 37(12): 1823-1832. IF 4.116. Q1.

• Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS ONE 2017; 12(9): e0184550. IF 2.806. Q1.

Ongoing Research Projects

• Cuantificación del HBsAg en pacientes con hepatitis B HBeAg-negativo, portadores inactivos o en tratamiento, para predecir la pérdida del HBsAg y correlación con los marcadores de fibrosis

- Fondo de Investigación Sanitaria. ISCIII (PI14/00540)

- From 2015 to 2018